Disc Medicine Shares Rise 39% on Positive Phase 3 Trial Results
Disc Medicine reported positive Phase 3 results for its erythropoietic protoporphyria treatment. Shares gained 39% to $78.88 on Monday and were roughly flat year to date.
Story updates
03:28:30 PM UTC
SquawkNews
By Mackenzie TatananniDisc Medicine is getting a second shot at bringing its lead asset to market following favorable trial results for its blood-disorder drug, bitopertin.Disc said Monday that it plans to reapply for Food and Drug Administration approval after a late-stage trial met its primary an…
Kelly CloonanShares of Disc Medicine rose after the company reported positive results from a Phase 3 trial for its treatment for erythropoietic protoporphyria, a rare and life-threatening disease.The stock gained 39% to $78.88 on Monday. Shares are now roughly flat year to date.Disc Medicine said t…